The last couple of quarters have been very favorable for Eli Lilly and Company (NYSE:LLY) and its position in the obesity and adjacent markets. The main competitor Novo Nordisk A/S (NVO ...

Pharmaceutical giant Eli Lilly and Co. sued Willow Health Services and three other companies in federal court in New Jersey and California, accusing them of selling unapproved compounded ...

Chief executive officers from Nvidia Corp., Johnson & Johnson, Eli Lilly & Co., General Electric Co. and SoftBank Group Corp. are among corporate leaders slated to visit the White House on ...

Pharmaceutical company Eli Lilly announced promising clinical trial results this week for a daily pill to treat obesity and diabetes. Besides the good news of minimal side effects and impressive ...

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the stock. Despite broader market uncertainties, the company ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

Patents, economies of scale, and a powerful distribution network support Eli Lilly’s wide moat. Lilly’s patent-protected drugs carry strong pricing power, which enables the firm to generate ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share ...

Eli Lilly (LLY) shares dip after HSBC double downgraded the stock to reduce — a sell-equivalent rating — from buy, saying the drugmaker’s risk-reward “is not attractive.” - Peloton ...